Cargando…
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion and immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show that PD-1 contributes to th...
Autores principales: | Yang, Riyao, Sun, Linlin, Li, Ching-Fei, Wang, Yu-Han, Yao, Jun, Li, Hui, Yan, Meisi, Chang, Wei-Chao, Hsu, Jung-Mao, Cha, Jong-Ho, Hsu, Jennifer L., Chou, Cheng-Wei, Sun, Xian, Deng, Yalan, Chou, Chao-Kai, Yu, Dihua, Hung, Mien-Chie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864927/ https://www.ncbi.nlm.nih.gov/pubmed/33547304 http://dx.doi.org/10.1038/s41467-021-21099-2 |
Ejemplares similares
-
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021) -
Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death
por: Yang, Riyao, et al.
Publicado: (2022) -
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity
por: Sun, Xian, et al.
Publicado: (2023) -
Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
por: Zheng, Shuang, et al.
Publicado: (2023) -
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
por: Wang, Ying-Nai, et al.
Publicado: (2020)